Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics Reports Inducement Grants [Yahoo! Finance]